Jump to start of content

Complete requirements by 12/31/19 to avoid a change in certification status Expand/Collapse the ABIM alert.

Sign in to your Physician Portal to view any remaining requirements for the year. Not completing these requirements by 12/31/19 could result in a change to your certification status.

ABIM Scheduled Maintenance... Expand/Collapse the ABIM alert.

ABIM.org will be going through scheduled maintenance from 6 p.m. ET, Sat., 12/14 to 6 a.m. ET, Sun., 12/15. During this time, the ABIM Physician Portal will be unavailable.
We apologize for any inconvenience this may cause. Thank you for your patience.

Breadcrumb trail:

Cardiovascular Board

Expand All | Collapse All

Olakunle Akinboboye, MD, Chair

Olakunle Akinboboye, MDDr. Akinboboye is board certified in Cardiovascular Disease and Sleep Medicine. He is a Clinical Associate Professor of Medicine at New York University (NYU). He is also the Medical Director of Queens Heart Institute/Laurelton Heart Specialist P.C. in Rosedale, Queens, New York.

Dr. Akinboboye is Chair of the American Board of Internal Medicine Cardiovascular Board and a member of the ABIM Council. He is also a member of the Association of Black Cardiologists (ABC) Executive Committee, where he serves as Chair of the Clinical Trials Committee. He also serves on the International Board of Governors of the American College of Cardiology (liason for Africa). He served as the President of the ABC from 2012 to 2014.

He received a humanitarian award from the College of Medicine at University of Ibadan in Nigeria in 2005 for his ongoing efforts to spread expertise in the techniques of cardiopulmonary resuscitation in Nigeria. He also received an award from ABC for his dedicated service as a board member from 1999 to 2005.

Dr. Akinboboye received his medical degree from the College of Medicine at the University of Ibadan. He completed his internal medicine residency and part of his cardiology fellowship at the Nassau County Medical Center, State University of New York at Stony Brook. He subsequently moved to Columbia University, where he completed his fellowship in cardiology with one year of dedicated training in nuclear cardiology and another year of training in advanced echocardiography. Dr. Akinboboye obtained a master's degree in public health from Columbia University. He also received a master's degree in business administration from Columbia Business School.

As of April 2019, Dr. Akinboboye reported the following external relationships:

Funding for clinical trial expenses and staff, paid to Queens Heart Institute, from the following companies:

  • AstraZeneca, for a study of the effects of exenatide in lowering cardiovascular events in patients with type 2 diabetes mellitus (EXSCEL).
  • Novartis, for a study of the effectiveness of angiotensin-neprilysin inhibition versus enalapril in heart failure (PARADIGM-HF).

Attendance at investigators’ meetings, with compensation for travel expenses from the following companies:

  • Cytokinetics, for a study to evaluate the effect of treatment with omecamtiv mecarbil compared with placebo on exercise capacity as determined by cardiopulmonary exercise testing following 20 weeks of treatment with omecamtiv mecarbil or placebo.

Craig Beam

Craig BeamCraig Beam is President of Petra ICS. Mr. Beam has overseen the development and management of a broad range of real estate with a focus on healthcare and institutional projects. Mr. Beam’s involvement in healthcare development includes the planning and development of hospital, medical office and ambulatory facilities. He is nationally recognized for his ability to lead assignments that are complex in program, finance and construction. He has over 30 years practicing nationally and internationally.

Mr. Beam started his career in real estate in 1977 as Chief Financial Officer of Concordia Development, a real estate development company based in Southern California. He then founded his own firm, Beam & Associates starting in 1983. At Beam had overall responsibility for the consulting, development, leasing and brokerage divisions of the firm. The firm was consistently ranked in the top 5 health care program and project management firms in the US. He merged this firm with Hammes Company in 1998 which created the largest healthcare project management firm in the United States. Mr. Beam has worked for major systems including Saint Joseph Health System of Orange, Ascension Health, MedStar and New York Presbyterian as well as academic centers such as Stanford, University of California San Francisco and Northwestern. Mr. Beam is a licensed California real estate broker and holds the professional designation of Counselor of Real Estate.

In addition to his real estate activities he has served on numerous boards including the advisory board to the Director of the National Institutes of Health, UniHealth, Pacificare and Martin Luther Hospital. He is past Chairman of the Board of the American Heart Association and is past Treasurer of the World Heart Federation.

Mr. Beam received a bachelor of arts degree in Business Administration from California State University in Fullerton, California

As of February 2019, Mr. Beam reported the following external relationships:

Mr. Beam serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Heart Association, Chair of the Hospital Accreditation and Certification Committee, Member of the Quality Oversight Committee, Member of the Corporate Operations Oversight Committee, receiving reimbursement for travel expenses.
  • Hospital Association of Southern California, Board Member for AllHealth, receiving per diem for attending board meetings.
  • Californians for Patient Care, Member Board of Directors, Member of Patient Safety Advocacy Group, receiving reimbursement for travel expenses.

Hugh G. Calkins, MD

Hugh Calkins, MDDr. Calkins, a board certified cardiologist and electrophysiologist, is the Nicholas J. Fortuin M.D. Professor of Cardiology and Professor of Medicine at the Johns Hopkins University School of Medicine. He also is the Director of the Clinical Electrophysiology Laboratory, the Arrhythmia Service and the Arrhythmogenic Right Ventricular Dysplasia Program at the Johns Hopkins Hospital. His academic career has focused on clinical electrophysiology.

Dr. Calkins' first faculty position was at the University of Michigan where he served as Director of the Pacemaker and Device Service. He was recruited to Johns Hopkins in 1992 as an Associate Professor of Medicine and Director of the Electrophysiology Service.

Currently, Dr. Calkins serves as a member of the American Board of Internal Medicine (ABIM) Cardiovascular Board and is former Chair of the ABIM Clinical Cardiac Electrophysiology Self-Assessment Committee. He has previously served as a member of the ABIM Cardiovascular Board Clinical Cardiac Electrophysiology Exam Committee. Dr. Calkins is a past President of the Heart Rhythm Society.

Dr. Calkins graduated magna cum laude with highest honors in chemistry from Williams College. He then attended Harvard Medical School before training in internal medicine at the Massachusetts General Hospital. He received his cardiology fellowship training at Johns Hopkins. Dr. Calkins trained in electrophysiology at Johns Hopkins and at the University of Michigan.

As of April 2019, Dr. Calkins reported the following external relationships:

Service on data and safety monitoring boards for the following companies, with no compensation to date:

  • St. Jude, for a ventricular tachycardia ablation trial.

Service on a research-related expert panel or advisory board for the following companies, with honoraria:

  • AtriCure, for advisory role to help design a clinical trial of surgical atrial fibrillation ablation.
  • Medtronic, for serving on their advisory board.
  • Daiichi Sankyo, for assisting in a survey designed to evaluate physician knowledge regarding atrial fibrillation management.

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, with honoraria:

  • Biosense Webster
  • Abbott
  • Boston Scientific

Teaching in satellite symposia funded by the following companies, with compensation for travel expenses and honoraria:

  • Medtronic, for speaking at symposia in New York City and Florida regarding atrial fibrillation management.
  • Boehringer Ingelheim, for speaking at several satellite symposia.
  • Biosense Webster, for a course in March 2019.

Providing FDA-required training in the use of devices with compensation from the following companies:

  • Boston Scientific, attended a Watchman Training meeting, receiving reimbursement for travel expenses.

Suzanne A. Feigofsky, MD

Dr. Feigofsky is an Electrophysiologist at the Iowa Heart Center in Carroll, Iowa. Previously she spent a decade in Orange County, CA in private practice. Dr. Feigofsky is board certified in cardiology and electrophysiology and currently serves as a member of the Heart Rhythm Society (HRS) communications committee and was recently appointed to the American College of Cardiology (ACC) Women in Cardiology Leadership Council. She also serves as a member of the American Board of Internal Medicine Cardiovascular Disease Specialty Board.

Dr. Feigofsky completed medical school at the University of Florida in Gainesville, FL and stayed on in Gainesville for internship, residency and fellowship training. Her clinical interests include syncope, POTS, as well as heart failure and cardio-oncology. In her free time, she enjoys the practice of yoga, cycling and is a beginning runner. To balance those activities, she enjoys baking homemade bread and cookies.

As of November 2018, Dr. Feigofsky reported the following external relationships:

Funding for clinical trial expenses, paid to the Iowa Heart Center, from the following companies:

  • Boston Scientific, for a trial to evaluate the use of antitachycardia pacing in treating ventricular arrhythmias.
  • Medtronic, for trial of an implantable cardiac defibrillator to predict arrhythmias.

John M. Herre, MD

Dr. John M. Herre received his undergraduate degree from Carnegie-Mellon University in 1973 and his Doctor of Medicine from Vanderbilt University in 1977. He completed training in Internal Medicine, Cardiology and Cardiac Electrophysiology at Baylor College of Medicine in 1983. He served on the faculty of the Medical College of Virginia from 1983 to 1985 and served on the faculty of the University of California, San Francisco, from 1985 to 1988 before moving to Norfolk, Virginia, where he started the Cardiac Electrophysiology program at Sentara Norfolk General Hospital.

Dr. Herre's interest in advanced heart failure began with the founding of the Heart Transplant program at Sentara Norfolk General Hospital in 1989. He served as Program Director for the Heart Transplant Program from 2003 until 2017. He is certified by the American Board of Internal Medicine in Internal Medicine, Cardiology and Advanced Heart Failure/Transplant Cardiology and served on the Test Writing Committee for Advanced Heart Failure/Transplant Cardiology form 2011 until 2017. He is currently a member of the American Board of Internal Medicine Cardiovascular Disease Board.

In 2006, Dr. Herre co-founded the Sentara Cardiovascular Research Institute and continues to serve as its Scientific Director. Dr. Herre has served on the Thoracic Organ and Membership and Professional Services Committees of the United Network of Organ Sharing. He is Chairman of the Board of Directors of LifeNet Health, a not-for-profit Organ Procurement Organization and leader in bio-implant technologies and cellular therapies. Dr Herre is a Professor of Medicine at Eastern Virginia Medical School and served as Chief, Division of Cardiology, from 2000 to 2010. He is Chair of the Institutional Review Board at EVMS and is an author of more than 100 publications in the areas of cardiac electrophysiology and heart failure. Dr Herre is a member of Sentara Cardiology Specialists and continues to care for patients with advanced heart failure, mechanical circulatory support and heart transplantation.

As of October 2018, Dr. Herre reported the following external relationships:

Funding for clinical trial expenses, staff and salary support, paid to Sentara Norfolk General Hospital, from the following companies:

  • Boston Scientific, for a clinical trial of a subcutaneous implantable cardioverter-defibrillator in the management of heart failure.
  • LivaNova, for a clinical trial of a vagal nerve stimulator in heart failure.

Service on data and safety monitoring boards for the following companies, with honoraria:

  • Medtronic, for a clinical trial of resynchronization after myocardial infarction.

Post-marketing clinical research funding for clinical trial expenses, staff and salary support, with funding provided to Sentara Norfolk General Hospital, from the following companies:

  • Boston Scientific, for a post-marketing study of the subcutaneous implantable cardioverter-defibrillator.

Dr. Herre serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • LifeNet Health, Board of Directors, Chairman, receiving reimbursement for travel expenses, per diem for attendance at board meetings, and honoraria.

Rowlens M. Melduni, MD

Dr. Melduni is an Associate Professor of Medicine and faculty in the Department of Cardiovascular Medicine at Mayo Clinic School of Medicine, Rochester, MN. He is board certified in Internal Medicine, Cardiovascular Disease and Adult Comprehensive Echocardiography. Dr Melduni is the Director of the cardioversion unit at the Mayo Clinic Rochester. He is the founder and president and CEO of Clinicians of the World and serves on the American Board of Internal Medicine (ABIM) Cardiovascular Board.

Dr. Melduni's research interests include the pathogenetic mechanism of atrial fibrillation, epidemiology and prognosis of atrial fibrillation and discovery of biomarkers of atrial fibrillation. He has authored numerous peer-reviewed publications, which have helped to improve our understanding of the mechanisms of atrial fibrillation, which has perplexed clinicians for quite some time. His work has recently received a major funding award from the National Institute of Health to examine the role of autoimmune mechanisms in the pathogenesis of atrial fibrillation. He was named a Rising Star Investigator by the American Society of Echocardiography in 2018.

Dr. Melduni received his medical degree from the University of Florida in Gainesville, Florida. He completed his internal medicine internship and residency at Boston University Medical Center and obtained his Cardiology training at Albert Einstein University Hospital and went on to complete subspecialty fellowship in Echocardiography at the Mayo Clinic Rochester. He received his master's degree in public health from the Harvard University School of Public Health in 2012.

As of October 2018, Dr. Melduni reported no external relationships:

Susan A. Moore-Gibbs, ARNP, Ph.D

Susan A. Moore-Gibbs, ARNP, Ph.DDr. Moore-Gibbs, a board certified Adult-Gerontology Primary Care Nurse Practitioner, practices at Sanger Heart & Vascular Institute in Charlotte, North Carolina. For the past 25 years, her career has centered on the care of cardiovascular patients and the education of nurses and other allied health professionals. Much of her time has been devoted to the care of patients with heart failure.

Dr. Moore-Gibbs currently serves as the Advanced Clinical Practitioner (ACP) Director for the Atrium Health’s Center for Advanced Practice Cardiology ACP Fellowship. She serves as faculty in the School of Nursing at the University of Southern Maine. She was instrumental in the development of the Heart Failure Program at Carolinas Medical Center and was lead program coordinator for seven years prior to pursuing her Masters Degree.

Dr. Moore-Gibbs is a member of the American Board of Internal Medicine Cardiovascular Board. She is the current Past President of the Metrolina Coalition of Nurse Practitioners. She is the Past Treasurer and Chair of the 2020 Annual Meeting Committee of the American Association of Heart Failure Nurses.

Dr. Moore-Gibbs earned her bachelor of science degree in nursing from the University of North Carolina at Charlotte in 1993. She completed her master of science degree in nursing with a dual degree as an Adult Nurse Practitioner and Clinical Nurse Specialist at the University of North Carolina at Charlotte in 2004. She obtained board certification as an Adult Nurse Practitioner in 2004 and Gerontological Nurse Practitioner in 2011. She completed her Doctorate of Nursing Practice at Duke University in May 2017.

As of January 2017, Ms. Moore reported the following external relationships:

Dr. Moore-Gibbs serves in a significant role with the following organization, receiving compensation as listed:

  • Metrolina Coalition of Nurse Practitioners, Treasurer, without compensation.

Dr. Moore-Gibbs is a guest lecturer for the American Association of Heart Failure Nurses annual review course for the Certified Heart Failure Nurse Exam for non-physicians. She receives reimbursement for travel expenses.

Andrea M. Russo, MD

Dr. Russo, board certified in Cardiovascular Disease and Clinical Cardiac Electrophysiology, is Professor of Medicine at Cooper Medical School of Rowan University, Director of Electrophysiology and Arrhythmia Services, Director of Cardiovascular Research and Director of the Clinical Cardiac Electrophysiology Fellowship Program at Cooper University Hospital in Camden, N.J. She previously joined the faculty at the University of Pennsylvania in 1997 and then the University of Medicine and Dentistry in New Jersey (UMDNJ)/Robert Wood Johnson Medical School at Cooper University Hospital in Camden, N.J. in 2009. Dr. Russo serves as a member of the American Board of Internal Medicine Cardiovascular Disease Board and previously served on the ABIM Cardiovascular Test Writing Committee and the ABMS Continuing Board Certification Vision for the Future Commission.

She is currently the President-Elect of the Heart Rhythm Society (HRS), member of the HRS Executive Committee, and member of the HRS Board of Trustees. She is also a current member of the American Heart Association (AHA) Atrial Fibrillation Systems of Care Advisory Committee and member of the American College of Cardiology (ACC) Cardiovascular Disease in Women Committee. She previously served on or chaired multiple HRS, ACC, or AHA committees, subcommittees or work groups. In addition, she has served as co-chair or member on several guideline, consensus document or Appropriate Use Criteria writing groups. Her areas of research interest include implantable cardioverter defibrillators, totally subcutaneous devices, atrial fibrillation, sex differences in arrhythmias and performance improvement activities.

Dr. Russo earned a B.S. degree in Microbiology at the University of Rochester in Rochester, NY and medical degree at the SUNY Health Sciences Center in Syracuse, NY. She completed an internal medicine residency at the Medical College of Pennsylvania in Philadelphia, Pennsylvania and Cardiovascular and Electrophysiology fellowships at the University of Medicine and Dentistry New Jersey in Camden, NJ.

As of October 2018, Dr. Russo reported the following external relationships:

Funding for clinical trial expenses, paid to Cooper University Hospital, from the following companies:

  • Boston Scientific, for a trial of a totally subcutaneous implantable cardioverter defibrillator.
  • Boehringer Ingelheim, for an anticoagulation registry.
  • Impulse Dynamics, for a trial of an implantable device to treat heart failure.

Work as an author or editor for following companies, with compensation as listed:

  • UpToDate, receiving compensation as an editor for chapters related to implantable cardioverter defibrillator therapy.

Dr. Russo serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • Heart Rhythm Society, Board of Trustees and President-Elect, receiving reimbursement for travel expenses.

Karen K. Stout, MD

Karen K. Stout, MDDr. Stout is a board certified cardiologist and is Director of the Adult Congenital Heart Disease Program and Director of the Adult Congenital Heart Disease (ACHD) Fellowship at the University of Washington Medical Center and Seattle Children's Hospital. She is a Professor of Cardiology in Medicine and Pediatrics at the University of Washington. Her academic interests are adult congenital heart disease, pregnancy and heart disease and echocardiography.

Dr. Stout is a member of the American Board of Internal Medicine (ABIM) Cardiovascular Board Adult Congenital Heart Disease Exam Committee and the ABIM Cardiovascular Board. She was Chair of the 2015 American College of Cardiology (ACC)/American Heart Association (AHA) Care of Adults with Congenital Heart Disease Guidelines Writing Committee and has chaired or been a member of several AHA scientific statements regarding congenital heart disease. She is a member of the ACC Adult Congenital and Pediatric Cardiology Committee and is Chair of the AHA ACHD Committee.

Dr. Stout earned her medical degree from the University of Arizona. She completed internal medicine residency and chief residency at Oregon Health and Sciences University and Cardiology fellowship at the University of Washington. She completed a congenital heart disease fellowship at Seattle Children's Hospital.

As of January 2017, Dr. Stout reported the following external relationships:

Work as an author or editor for following companies, with compensation as listed:

  • Elsevier, receiving royalties for a textbook that she edited.
  • UpToDate, receiving compensation for authorship.

Dr. Stout serves in significant roles with the following organizations, receiving compensation as listed:

  • American College of Cardiology, Member of Adult Congenital and Pediatric Cardiology Council, without compensation.
  • American Congenital Heart Association, Medical Advisory Board, without compensation.
  • American Heart Association, Puget Sound Chapter Board of Directors, without compensation.

James E. Tcheng, MD

James E. Tcheng, MDDr. Tcheng, a board certified internist, cardiologist, interventional cardiologist and informatician, is a Professor of Medicine and Professor of Community and Family Medicine (Informatics) at Duke University in Durham, North Carolina.

Currently, Dr. Tcheng serves as Chair of the American Board of Internal Medicine (ABIM) Cardiovascular Board Interventional Cardiology Exam Committee and is a member of the ABIM Cardiovascular Board. He is a member of the Lifelong Education Committee of the American College of Cardiology (ACC) and the ACC Publications and Editorial Coordination Committee, and the National Cardiovascular Disease Registry. He serves as Chair of the ACC Informatics and Health Information Technology Task Force and the ACC Digital Steering Committee.

He is an accomplished clinical trialist of cardiovascular therapeutics, particularly antithrombotic and interventional therapies in coronary artery disease. More recently, his career has focused on the representation and application of knowledge in electronic health record systems through the use of informatics.

Dr. Tcheng received his medical degree from Johns Hopkins University, and he completed his residency in internal medicine at Barnes Hospital, Washington University, St. Louis. He completed fellowship training in cardiology and interventional cardiology at Duke University.

As of January 2017, Dr. Tcheng reported the following external relationships:

Service on data and safety monitoring board for the following company, with honoraria:

  • AstraZeneca, for a study evaluating ticagrelor with aspirin versus ticagrelor alone in high-risk patients after coronary intervention.

Service on a research-related expert panel or advisory board for the following companies, with compensation as listed:

  • Philips Medical Systems, as a subject matter expert on the design and development of next generation cardiovascular information systems, receiving reimbursement for travel and honoraria.
  • Cardiovascular Systems, Inc., as a subject matter expert on the design and evaluation of clinical studies to advance the treatment of peripheral vascular and cardiovascular disease.

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following company, with reimbursement for travel expenses and honoraria

  • International Guidelines Central, providing consultative guidance in the redesign and updating of their web product portfolio for this publisher of Guideline “Pocket Cards.”

Work as an author or editor for following company, with compensation as listed:

Humana Press, receiving royalties for serving as an editor for Primary Angioplasty in Acute Myocardial Infarction.

Dr. Tcheng serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • American College of Cardiology, Committee Chair of Digital Steering Committee & Informatics and Health Information Technology Task Force, and National Cardiovascular Disease Registry Board Member, and member of the Science and Quality Oversight Committee, the Data Standards Task Force, the Lifelong Learning Oversight Committee, the Cardiovascular Training Council, and the Publications and Educational Coordination Committee, receiving reimbursement for travel expenses.